Dr. Cat Lutz is Co-PI of Project 2. Dr. Lutz has had scientific, operational and financial oversight of the Mouse Repository at The Jackson Laboratory (JAX) since 2008, being appointed Director in 2011. In 2012, Dr. Lutz launched the Rare and Orphan Disease Center at JAX, where she began working with multiple disease foundations and academic institutes to genetically engineer and procure mouse strains of biological and preclinical relevance to particular diseases. In 2013, Dr. Lutz established a new program at JAX for in vivo pharmacology services to test therapeutics in mouse models of neurological disease for biotech and pharmaceutical companies. She has more than 25 years of experience in mouse genetics and characterization of neurological phenotypes in mice. As part of the greater mouse repository effort, Dr. Lutz will facilitate the rapid characterization, standardization and consistent use of mouse models, with the aim of supporting reproducibility across laboratories and accelerating treatment discovery. Dr. Lutz has oversight of a growing collection of more than 8,500 unique strains (including over 1,700 live colonies) that are made available for distribution to the scientific community. Within the Genetic Resource Science department at JAX, Dr. Lutz has oversight of a team of 130 employees with grants and administrative budgets greater than $30M/year. Dr. Lutz also runs her own research laboratory at JAX with approximately 25 lab members. As a neuroscientist by training, her scientific interests are in the development of mouse models for different neurological diseases. Her lab has played a significant role in helping to establish and phenotypically validate disease-specific mouse resources that allow for cross comparative, longitudinal studies across a series of models. Her primary research focus is in diseases of motor neuron degeneration, including spinal muscular atrophy (SMA) and ALS. With the discovery of genetic loci that contribute to the susceptibility uncovered in human sequencing experiments, her lab has been using genome-editing technologies to engineer mouse models for ALS. Her recent publications in Neuron and Science involve the engineering of C9ORF72 models of ALS and frontotemporal dementia (FTD) and the incorporation of new genome editing technologies to rapidly create mouse models based on human mutation discovery.